1,3,4,5,-tetrahydrobenzo(c)(1,6)-naphthyridin-6-one | 497843-36-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1,3,4,5,-tetrahydrobenzo(c)(1,6)-naphthyridin-6-one
• 英文别名: 1,3,4,5-Tetrahydrobenzo[c][1,6]naphthyridin-6(2H)-one；2,3,4,5-tetrahydro-1H-benzo[c][1,6]naphthyridin-6-one
• CAS: 497843-36-4
• 化学式: C₁₂H₁₂N₂O
• 分子量: 200.24
• InChiKey: GJAHAFVXSLLAOG-UHFFFAOYSA-N

物化性质

• 沸点：
  481.2±45.0 °C(Predicted)
• 密度：
  1.28±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.3
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  41.1
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,3,4,5,-tetrahydrobenzo(c)(1,6)-naphthyridin-6-one 在 三乙胺 作用下， 生成 2-[3-(4-Pyrrolidin-1-yl-piperidin-1-yl)-propionyl]-1,3,4,5-tetrahydro-2H-benzo[c][1,6]naphthyridin-6-one
  参考文献：
  名称：

  Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones

  摘要：

  The 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-napthyridin-6-ones are presented as a potent class of PARP-1 inhibitors. Derivatives of these partially saturated aza-5[H]-phenanthridin-6-ones were designed and synthesized with tertiary amines for salt formation. thus enhancing aqueous solubility, iv formulation and their potential use in acute ischemic injuries (i.e., myocardial ischemia and stroke). We found that partial saturation of the C-ring results in derivatives that are several times more potent than the aromatic C-ring derivatives. The general synthetic routes are presented herein as well as thorough in vitro potencies and SAR discussion for selected derivatives. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00465-7
• 作为产物：
  描述：

  1-苄基-3-氧杂-4-哌啶甲酸乙酯 在 palladium on activated charcoal lithium hydroxide 、 四(三苯基膦)钯 、 四磷十氧化物 、 二苯基膦叠氮化物 、 氢气 、 sodium hydride 、 potassium carbonate 、 三乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 甲醇 、 乙二醇二甲醚 、 乙醚 、 甲苯 为溶剂， 生成 1,3,4,5,-tetrahydrobenzo(c)(1,6)-naphthyridin-6-one
  参考文献：
  名称：

  Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones

  摘要：

  The 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-napthyridin-6-ones are presented as a potent class of PARP-1 inhibitors. Derivatives of these partially saturated aza-5[H]-phenanthridin-6-ones were designed and synthesized with tertiary amines for salt formation. thus enhancing aqueous solubility, iv formulation and their potential use in acute ischemic injuries (i.e., myocardial ischemia and stroke). We found that partial saturation of the C-ring results in derivatives that are several times more potent than the aromatic C-ring derivatives. The general synthetic routes are presented herein as well as thorough in vitro potencies and SAR discussion for selected derivatives. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(03)00465-7

文献信息

• [EN] COMPOUNDS, DERIVATIVES, COMPOSITIONS, PREPARATION AND USES<br/>[FR] COMPOSES, DERIVES, COMPOSITIONS, LEUR PREPARATION ET LEURS UTILISATIONS
  申请人：GUILFORD PHARM INC

  公开号：WO2003014121A1

  公开（公告）日：2003-02-20

  This invention relates to compounds, pharmaceutical compositions, and methods of using the disclosed compounds for inhibiting PARP.

  本发明涉及化合物、药物组合物以及使用所披露的化合物抑制PARP的方法。
• US7247641B2
  申请人：——

  公开号：US7247641B2

  公开（公告）日：2007-07-24
• Design and synthesis of poly(ADP-ribose)polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evaluation of 1,3,4,5-Tetrahydro-benzo[c][1,6]- and [c][1,7]-naphthyridin-6-ones
  作者：Dana Ferraris、Rica Pargas Ficco、Thomas Pahutski、Susan Lautar、Shirley Huang、Jie Zhang、Vincent Kalish

  DOI：10.1016/s0960-894x(03)00465-7

  日期：2003.8

  The 1,3,4,5-tetrahydro-benzo[c][1,6]- and [c][1,7]-napthyridin-6-ones are presented as a potent class of PARP-1 inhibitors. Derivatives of these partially saturated aza-5[H]-phenanthridin-6-ones were designed and synthesized with tertiary amines for salt formation. thus enhancing aqueous solubility, iv formulation and their potential use in acute ischemic injuries (i.e., myocardial ischemia and stroke). We found that partial saturation of the C-ring results in derivatives that are several times more potent than the aromatic C-ring derivatives. The general synthetic routes are presented herein as well as thorough in vitro potencies and SAR discussion for selected derivatives. (C) 2003 Elsevier Ltd. All rights reserved.